Aspira Women’s Health (NASDAQ:AWH) Downgraded to “Sell” at StockNews.com

StockNews.com downgraded shares of Aspira Women’s Health (NASDAQ:AWH) from a hold rating to a sell rating in a report released on Friday.

Separately, Alliance Global Partners cut their price target on Aspira Women’s Health from $7.00 to $5.50 and set a buy rating for the company in a research note on Wednesday, August 14th.

Aspira Women’s Health Price Performance

Shares of AWH stock opened at $0.96 on Friday. The company has a 50 day moving average price of $1.19 and a 200-day moving average price of $2.36. Aspira Women’s Health has a 52 week low of $0.86 and a 52 week high of $6.59. The firm has a market capitalization of $11.98 million, a PE ratio of -0.66 and a beta of 1.48.

Aspira Women’s Health (NASDAQ:AWH) last posted its earnings results on Monday, August 12th. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.04. The company had revenue of $2.42 million during the quarter, compared to the consensus estimate of $2.60 million. During the same period last year, the firm posted ($0.28) EPS. Analysts anticipate that Aspira Women’s Health will post -1.26 earnings per share for the current year.

Institutional Trading of Aspira Women’s Health

A hedge fund recently raised its stake in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. increased its position in Aspira Women’s Health Inc. (NASDAQ:AWH) by 43.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 179,371 shares of the company’s stock after acquiring an additional 53,997 shares during the quarter. B. Riley Wealth Advisors Inc. owned about 1.73% of Aspira Women’s Health worth $732,000 at the end of the most recent quarter. Institutional investors and hedge funds own 12.19% of the company’s stock.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.